​

BeiGene (BGNE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BGNE Stock Forecast

BeiGene (BGNE) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $207.00, with a high of $207.00 and a low of $207.00. This represents a 12.07% increase from the last price of $184.71.

$140 $157 $174 $191 $208 $225 High: $207 Avg: $207 Low: $207 Last Closed Price: $184.71

BGNE Stock Rating

BeiGene stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (72.22%), 4 Hold (22.22%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 1 4 13 Strong Sell Sell Hold Buy Strong Buy

BGNE Price Target Upside V Benchmarks

TypeNameUpside
StockBeiGene12.07%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$271.25
Last Closing Price$184.71$184.71$184.71
Upside/Downside--46.85%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 256132--21
Dec, 247132--22
Nov, 247142--23
Oct, 247152--24
Sep, 247152--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 29, 2024Rebecca LiangBernstein$207.00$207.83-0.40%12.07%
Sep 18, 2024Reni BenjaminJMP Securities$288.00$197.5145.82%55.92%
Aug 23, 2024Matthew HarrisonMorgan Stanley$307.00$193.5758.60%66.21%
May 09, 2024Kelly ShiJefferies$283.00$164.4472.10%53.21%
Jun 30, 2023Rebecca LiangBernstein$196.00$178.469.83%6.11%
Oct 13, 2022Michael SchmidtGuggenheim$205.00$151.3035.49%10.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 29, 2024BernsteinMarket PerformMarket Performhold
Nov 13, 2024Cowen & Co.BuyBuyhold
Sep 18, 2024Johnson RiceMarket Performinitialise
Sep 18, 2024JMP SecuritiesMarket OutperformOutperforminitialise
Sep 18, 2024JMP SecuritiesMarket Outperforminitialise
Aug 23, 2024Morgan StanleyOverweightOverweighthold
Aug 08, 2024CitigroupBuyBuyhold
Jul 22, 2024JefferiesBuyBuyhold
May 09, 2024Cowen & Co.BuyBuyhold
May 09, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-17 $-9 $-1 $7 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.47$-1.17$-1.49$-8.45-----
Avg Forecast$-17.27$-12.14$-18.15$-8.14$-5.44$-0.67$3.44$8.91$8.76
High Forecast$-15.56$-10.93$-16.67$-3.45$-4.76$5.67$6.25$13.98$9.74
Low Forecast$-20.19$-14.19$-19.80$-9.86$-6.39$-9.45$-1.00$3.85$8.00
Surprise %-91.49%-90.36%-91.79%3.81%-----

Revenue Forecast

$0 $2B $3B $5B $7B $9B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$308.87M$1.18B$1.42B$2.46B-----
Avg Forecast$332.54M$1.20B$1.41B$2.42B$3.71B$4.66B$5.64B$6.96B$7.59B
High Forecast$375.78M$1.36B$1.51B$2.48B$3.72B$4.80B$6.12B$7.56B$8.24B
Low Forecast$307.14M$1.11B$1.33B$2.38B$3.70B$4.44B$5.26B$6.50B$7.08B
Surprise %-7.12%-2.07%0.19%1.43%-----

Net Income Forecast

$-3B $-2B $-900M $-100M $700M $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.60B$-1.41B$-2.00B$-881.71M-----
Avg Forecast$-1.80B$-1.04B$-1.77B$-881.71M$-581.51M$-506.21M$273.82M$930.56M$914.49M
High Forecast$-1.62B$-778.27M$-1.42B$-705.37M$-496.42M$591.51M$652.19M$1.46B$1.02B
Low Forecast$-2.11B$-1.30B$-2.12B$-1.06B$-666.60M$-986.79M$-104.54M$401.97M$834.59M
Surprise %-11.24%35.88%13.17%------

BGNE Forecast FAQ

Is BeiGene stock a buy?

BeiGene stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that BeiGene is a favorable investment for most analysts.

What is BeiGene's price target?

BeiGene's price target, set by 18 Wall Street analysts, averages $207 over the next 12 months. The price target range spans from $207 at the low end to $207 at the high end, suggesting a potential 12.07% change from the previous closing price of $184.71.

How does BeiGene stock forecast compare to its benchmarks?

BeiGene's stock forecast shows a 12.07% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for BeiGene over the past three months?

  • January 2025: 28.57% Strong Buy, 61.90% Buy, 9.52% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 31.82% Strong Buy, 59.09% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 30.43% Strong Buy, 60.87% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.

What is BeiGene’s EPS forecast?

BeiGene's average annual EPS forecast for its fiscal year ending in December 2024 is $-5.44, marking a -35.62% decrease from the reported $-8.45 in 2023. Estimates for the following years are $-0.67 in 2025, $3.44 in 2026, $8.91 in 2027, and $8.76 in 2028.

What is BeiGene’s revenue forecast?

BeiGene's average annual revenue forecast for its fiscal year ending in December 2024 is $3.71B, reflecting a 50.74% increase from the reported $2.46B in 2023. The forecast for 2025 is $4.66B, followed by $5.64B for 2026, $6.96B for 2027, and $7.59B for 2028.

What is BeiGene’s net income forecast?

BeiGene's net income forecast for the fiscal year ending in December 2024 stands at $-582M, representing a -34.05% decrease from the reported $-882M in 2023. Projections indicate $-506M in 2025, $273.82M in 2026, $930.56M in 2027, and $914.49M in 2028.